Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing next-generation allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for the treatment of cancer and autoimmune diseases. By advancing off-the-shelf cell therapies, the company aims to make innovative CAR T treatments more readily available, scalable, and accessible to patients who need them.

Its integrated research, development, and manufacturing capabilities support the discovery, clinical development, and production of investigational AlloCAR T candidates targeting blood cancers, solid tumors, and autoimmune diseases. Leveraging a fully in-house team of experts in cell therapy, translational research, and manufacturing, Allogene is developing therapies designed to overcome the limitations of traditional autologous CAR T treatments by enabling faster treatment availability, greater manufacturing consistency, and broader patient access.

Driven by a mission to lead the next generation of cell therapy, Allogene Therapeutics is committed to advancing innovative immunotherapies that have the potential to transform patient care. Through scientific excellence, integrated development, and pioneering research, the company is working to redefine the future of CAR T therapy and expand the possibilities of cell-based medicine.